Our Portfolio
Key Statistics
in revenue during LYFE holding Period
in revenue for LYFE portfolios
in global capital markets
sale to global strategic and financial sponsors
Our Portfolio
LYFE Capital invests in a strategic portfolio of leading healthcare companies. Our extensive ecosystem of experts and long-term investors also in-turn provides value for our portfolio companies.
Fong’s Engineering is a Singapore based specialized MedTech Contract Development and Manufacturing Organization (CDMO) with a strong foothold in the endoscopic sector.
Bora Pharmaceuticals is a leading global-focused drug development and manufacturing player with proven capabilities in M&A integration, CDMO operations, and commercial operations in North America.
ST Pharm is a South Korean leading CDMO player in the global oligonucleotide synthesis market with Strong partnerships with leaders such as GSK, Novartis, Roche, and BMS.
Jeisis medical is a South Korean leading energy based medical aesthetic device player featuring diversified product lines and fast iteration speed.
Noah Medical is a California based surgical robotic player focusing in endoluminal robotics.
Profound Bio is a Seattle headquartered ADC platform with leading assets target Fra in Phase I/II and PTK78 in Phase I.
Edge Medical is a China based surgical robotic company that received approvals for both its multi-port and single-port endoscopy systems.
Brightech is a New Jersey based high growth and end-to-end data service CRO leveraging Asia to improve operation efficiency.
Our Funds
LYFE is currently managing USD 2Bn with global institutional investors including pension, endowment, fund of funds, renowned family offices, and advisors. Our latest Fund IV closed in 2022 with USD 935Mn.